New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
20:06 EDTDHRDanaher sees Q4 EPS above high end of 80c-85c range, consensus 83c
Sees higher than expected core revenue growth in Q4, consensus $4.47B. Company says CEO H. Lawrence Culp to comment on results at JPMorgan Healthcare Conference January 9.
News For DHR From The Last 14 Days
Check below for free stories on DHR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
16:36 EDTDHRDanaher coverage resumed with a Buy at Stifel
Subscribe for More Information
11:23 EDTDHRDanaher says "very busy" on M&A front
says "very, very busy" on M&A side. Sees ability to get deals done. Says July, August, "a little better than we thought" in U.S., Europe "okay." Says has a "little bit" of exposure to Russia, "hurting us a little bit" right now. Comments made at the Morgan Stanley Laguna Conference.
September 15, 2014
08:56 EDTDHRDanaher: It's important not to read too much into 2 deals for company direction
Subscribe for More Information
08:49 EDTDHRDanaher expects global dentistry market to grow 3%-5%
Subscribe for More Information
08:47 EDTDHRDanaher expects Nobel Biocare acquisition to be accretive to EPS by 5c in 2015
Subscribe for More Information
07:42 EDTDHRMorgan Stanley to hold a conference
Subscribe for More Information
05:58 EDTDHRDanaher to host conference call
Subscribe for More Information
05:20 EDTDHRDanaher to acquire Nobel Biocare Holding for CHF 17.10 per share
Danaher has entered into a definitive transaction agreement with Nobel Biocare Holding AG pursuant to which Danaher or one of its direct or indirect subsidiaries will commence a tender offer for all publicly held registered shares of Nobel Biocare in an all-cash transaction valued at approximately $2.2B. The deal is expected to widen Danaher's market presence in the global dental industry and allow Nobel Biocare to accelerate its strategic objectives and future growth. Under the terms of the transaction agreement, Danaher will commence a voluntary all-cash public tender offer of CHF 17.10 per Nobel Biocare share to purchase all of Nobel Biocare's publicly held registered shares. The pre-announcement of the public tender offer is published today. The offer prospectus is expected to be published on or around October 1 and the offer period during which Nobel Biocare shareholders may tender their registered shares is expected to start on or around October 16. In 2013, Nobel Biocare generated annual revenues of approximately $750M. Nobel Biocare would become part of Danaher's $2.2B Dental segment and complements Danaher's position in the implant industry. The Nobel Biocare board has recommended that Nobel Biocare shareholders accept and tender their shares into the offer, which represents a premium of approximately 23% to Nobel Biocare's closing price on July 28, the day before market speculation began regarding a potential sale of the company, or 28% on the basis of the 60 day volume-weighted average price on that date. The offer is expected to be completed in late 2014 or early 2015.
05:17 EDTDHRDanaher to acquire Nobel Biocare Holding for CHF 17.10 per share
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use